Andy Hsieh
Stock Analyst at William Blair
(1.85)
# 3,268
Out of 5,055 analysts
13
Total ratings
57.14%
Success rate
0.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Upgrades: Outperform | n/a | $22.56 | - | 2 | Nov 3, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Outperform | n/a | $11.07 | - | 1 | Feb 28, 2025 | |
| SKYE Skye Bioscience | Initiates: Outperform | n/a | $1.30 | - | 1 | Feb 28, 2025 | |
| ALT Altimmune | Initiates: Market Perform | n/a | $4.17 | - | 1 | Feb 28, 2025 | |
| GPCR Structure Therapeutics | Initiates: Outperform | n/a | $36.82 | - | 1 | Feb 28, 2025 | |
| BIOA BioAge Labs | Initiates: Market Perform | n/a | $7.80 | - | 1 | Feb 28, 2025 | |
| MRSN Mersana Therapeutics | Initiates: Outperform | n/a | $27.92 | - | 1 | Feb 6, 2025 | |
| PYXS Pyxis Oncology | Downgrades: Market Perform | n/a | $4.36 | - | 1 | Nov 21, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | n/a | $53.01 | - | 1 | Sep 29, 2023 | |
| FGEN FibroGen | Downgrades: Market Perform | n/a | $8.69 | - | 2 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.27 | - | 1 | Feb 21, 2023 |
Terns Pharmaceuticals
Nov 3, 2025
Upgrades: Outperform
Price Target: n/a
Current: $22.56
Upside: -
Corbus Pharmaceuticals Holdings
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $11.07
Upside: -
Skye Bioscience
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.30
Upside: -
Altimmune
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $4.17
Upside: -
Structure Therapeutics
Feb 28, 2025
Initiates: Outperform
Price Target: n/a
Current: $36.82
Upside: -
BioAge Labs
Feb 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $7.80
Upside: -
Mersana Therapeutics
Feb 6, 2025
Initiates: Outperform
Price Target: n/a
Current: $27.92
Upside: -
Pyxis Oncology
Nov 21, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.36
Upside: -
Lantheus Holdings
Sep 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $53.01
Upside: -
FibroGen
Jun 26, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.69
Upside: -
Feb 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.27
Upside: -